Laureate Pharma Will Continue to Manufacture Cytogen’s ProstaScint
Companies ink renewal agreement.!--h2>
Laureate Pharma renewed its agreement with Cytogen for the cGMP manufacture of ProstaScint®, Cytogen's Mab immunoconjugate that is used for imaging in patients diagnosed with prostate cancer.
Under the agreement, Laureate will provide cGMP protein production and purification, conjugation of Cytogen's linker chelator, and aseptic filling services to support Cytogen's commercial ProstaScint requirements.